Minapharm Pharmaceuticals (CAI:MIPH) Other Current Payables: E£57 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£722.56
GF Value E£362.67
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Other Current Payables?

Minapharm Pharmaceuticals CAI:MIPH +2.17% 41 Other Current Payables is E£57 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.67 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's Other Current Payables for the quarter that ended in Dec. 2025 was E£57 Mil.

Minapharm Pharmaceuticals's quarterly Other Current Payables declined from Jun. 2025 (E£113 Mil) to Sep. 2025 (E£62 Mil) and declined from Sep. 2025 (E£62 Mil) to Dec. 2025 (E£57 Mil).

Minapharm Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 (E£18 Mil) to Dec. 2024 (E£68 Mil) but then declined from Dec. 2024 (E£68 Mil) to Dec. 2025 (E£57 Mil).

Minapharm Pharmaceuticals Other Current Payables Related Terms

Minapharm Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Other Current Payables Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
25.93 33.12 18.48 68.28 57.01

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.28 45.16 113.17 62.48 57.01
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of E£57 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Other Current Payables of E£57 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Other Current Payables too high?
Minapharm Pharmaceuticals' current Other Current Payables is E£57 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Other Current Payables compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Other Current Payables of E£57 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Other Current Payables is E£57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.67, compared to a current price of E£722.56 — trading 99.2% above its estimated fair value. The current Other Current Payables is E£57 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Other Current Payables is E£57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£722.56 is trading 99.2% above its estimated GF Value™ of E£362.67. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Other Current Payables: E£57 Mil
  • GF Value™: E£362.67 vs. price of E£722.56 (99.2% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£722.56
Price
E£362.67
GF Value